Bangalore, July 12, 2010: Several exciting new results and data presentations from Suven’s portfolio of investigational neuroscience new chemical entities (NCEs) will be presented at International Conference on Alzheimer’s Disease (ICAD) at Honolulu, US, on July 12-15, 2010. ICAD is the annual International conference of the Alzheimer’s association and more than 10,000 neuro scientists, clinicians, corporate senior management from all over the world covering all the major pharma, biotech and academic research Institutions would attend this meeting.

Suven’s portfolio has an excellent new molecule which not only treats the cognitive impairment in Alzheimer’s disease symptomatically but also possibly useful in reducing the disease progression. Suven scientists are presenting exciting data on this molecule and other NCE’s on cognitive impairment and memory-related disorders, depression and pain.

Alzheimer’s disease has a significant unmet medical need for which current treatment options are insufficient. Suven has a number of in-house drug discovery programs in the area of cognition, focusing on novel approaches that may lead to the development of new therapies for patients in addition to the current clinical candidate SUVN-502.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.